WebeTheRNA immunotherapies has 4 current employee profiles, including Quality Assurance & Regulatory Affairs Sonja Van Meirvenne. Sonja Van Meirvenne Quality Assurance & Regulatory Affairs. Dirk Reyn CEO. Luc Lammens Finance. Kris Thielemans Founder and Chief Scientific Officer. WebeTheRNA immunotherapies' mission is to help patients to overcome certain cancers and infectious diseases by developing novel immunotherapies that target the fundamental … eTheRNA immunotherapies has raised a total of $111.9M in funding over 5 … eTheRNA immunotherapies has 4 current employee profiles, including Quality … eTheRNA immunotherapies is actively using 55 technologies for its website, … eTheRNA immunotherapies raised €34,000,000 / Series B from BNP … Companies like eTheRNA immunotherapies include Excision BioTherapeutics and …
Belgian CDMO offers new LNP service as demand for RNA …
WebI was part of the team researching solutions for PET/CT, leading to contributions in current GE products for scatter correction, image reconstruction and motion correction. In 2011 I moved back to academia, first at King's College London and now at UCL, where I lead the UCL medical physics group at the Institute of Nuclear Medicine. WebMar 4, 2024 · Steven Powell, CEO of eTheRNA immunotherapies, commented: "The potential of combining eTheRNA's mRNA and LNP technologies with ConserV's antigens is exciting. The collaboration has the potential ... tobias weber trumpf
Mymetics Corporation (MYMX): Background on EtheRNA ... - InvestorsHub
WebThe company's immunotherapies contain proprietary mRNA-based technology that boosts dendritic cells leading to a comprehensive, … WebDeveloper of mRNA-based therapeutics and vaccines intended to treat patients with respiratory disorders and infectious diseases. The company's novel, proprietary, and best-in-class mRNA-modification technology and LNP formulation and delivery platforms provide highly versatile, multi-route, multi-cargo delivery options for intramuscular ... WebParis, France – 21 st July 2024.. Coave Therapeutics (pronounced ‘cove’; formerly Horama), a clinical stage biotechnology company focused on developing life changing gene therapies in rare Ocular and CNS (Central Nervous System) diseases, announces a €21.2 million ($25.1 million) expansion of its Series B funding round, bringing the total raised to €33.1 … tobias weber artemed